Abstract
ObjectiveThe heterogeneity of systemic lupus erythematosus (SLE) poses a challenge in clinical care. Several treatment options are available, but data on immunomodulating drug survival in SLE is limited, warranting further...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
